Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Enterprise Value (2019 - 2023)

Alx Oncology Holdings' Enterprise Value history spans 5 years, with the latest figure at -$190.0 million for Q3 2023.

  • For Q3 2023, Enterprise Value rose 33.31% year-over-year to -$190.0 million; the TTM value through Sep 2023 reached -$190.0 million, up 33.31%, while the annual FY2022 figure was -$266.2 million, 26.8% up from the prior year.
  • Enterprise Value for Q3 2023 was -$190.0 million at Alx Oncology Holdings, up from -$212.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$9.0 million in Q4 2019 and bottomed at -$434.2 million in Q4 2020.
  • The 5-year median for Enterprise Value is -$284.9 million (2022), against an average of -$280.1 million.
  • The largest annual shift saw Enterprise Value plummeted 4715.56% in 2020 before it skyrocketed 33.31% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$9.0 million in 2019, then tumbled by 4715.56% to -$434.2 million in 2020, then rose by 16.25% to -$363.7 million in 2021, then rose by 26.8% to -$266.2 million in 2022, then grew by 28.62% to -$190.0 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Enterprise Value are -$190.0 million (Q3 2023), -$212.8 million (Q2 2023), and -$227.9 million (Q1 2023).